Nothing implied I love lecanamab despite the presentation being a complete and thorough example of how these things are done.
My post was in reply to a statement about Anavex comparing Odds Ratios with Lecanamab, where no Odds Ratios were presented.
As an investor I did take a small position in Biogen because it seems clear to me that lecanamab will gain full approval in the US, but possibly not by EMA or Japan.
I may or may not keep that position leading up to the FDA’s second decision on this.
Market Data 
Markets 
AI
